Two weekly injections dominate the weight-loss conversation. Here is how tirzepatide and semaglutide actually differ — mechanism, trial data, side effects, and how I help patients choose between them.
Almost every new patient at Elios arrives with the same question: which weight-loss shot is better? It is a fair question, and the honest answer is more useful than a winner. Both medications are legitimate, both are FDA-approved for chronic weight management, and both work far better inside a real plan than they do on their own.
Zepbound (tirzepatide) produces more weight loss on average. Wegovy (semaglutide) has a longer real-world track record and strong cardiovascular outcome data. The right choice depends on your history, your tolerance, your coverage, and how closely you are followed during titration.
Semaglutide mimics GLP-1, a gut hormone released after eating. It slows gastric emptying, signals fullness to the brain, and improves insulin response to meals. Tirzepatide does all of that and adds GIP receptor activity — a second incretin pathway that appears to amplify appetite suppression and improve how fat tissue handles nutrients. That extra pathway is the leading explanation for the difference in average results.
In SURMOUNT-1, participants on tirzepatide lost roughly 20% of body weight over 72 weeks. In STEP-1, semaglutide participants lost roughly 15% over 68 weeks. The SURMOUNT-5 head-to-head trial compared them directly and favored tirzepatide by a meaningful margin. Semaglutide, meanwhile, has the SELECT trial behind it, which showed reduced major cardiovascular events in people with overweight or obesity and established heart disease — a distinct and important benefit.
Averages hide range. In every one of these trials some participants lost far more than the mean and some lost very little. Which is exactly why the follow-up matters more than the brand name.
| Zepbound | Wegovy | |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Administration | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Maintenance dosing range | 5–15 mg weekly | 1.7–2.4 mg weekly |
| Average weight loss in trials | ~20% of body weight (72 wks) | ~14% of body weight (68–72 wks) |
| Titration period | Roughly 4–5 months to top dose | Roughly 4–5 months to top dose |
| Most common side effects | Nausea, constipation, diarrhea, reflux | Nausea, constipation, diarrhea, reflux |
The two profiles look remarkably similar. Nausea, constipation, diarrhea, reflux, and fatigue are common, usually worst in the week or two after a dose increase, and usually manageable with slower titration, smaller meals, adequate fiber, and hydration. Less common but serious risks include pancreatitis, gallbladder disease, and worsening of diabetic retinopathy in some patients. Both carry a boxed warning regarding thyroid C-cell tumors observed in rodents, and neither is appropriate with a personal or family history of medullary thyroid carcinoma or MEN2.
The under-discussed risk is muscle loss. A meaningful share of rapid weight loss on either drug can be lean mass, which is why protein targets and resistance training are non-negotiable parts of the plan rather than optional extras.
I look at labs first — A1c, fasting insulin, lipids, liver enzymes, thyroid. Marked insulin resistance nudges me toward tirzepatide. Established cardiovascular disease nudges me toward semaglutide, given the SELECT data. A history of difficult GI tolerance means starting lower and moving slower regardless of which we pick. Coverage and supply are real constraints, and I would rather have you on the medication you can obtain consistently than the theoretically superior one you cannot fill.
Then we build the rest: nutrition around your labs and your life, a protein floor, strength work, sleep, and check-ins frequent enough to catch problems while they are still small. That scaffolding is what turns a prescription into a durable result.
In the head-to-head SURMOUNT-5 trial, tirzepatide (Zepbound) produced greater average weight loss than semaglutide (Wegovy) over 72 weeks — roughly 20% of body weight versus roughly 14%. Averages are not predictions, though: individual response varies widely, and the medication you tolerate and stay on consistently is the one that works best for you.
Semaglutide (Wegovy) is a GLP-1 receptor agonist. Tirzepatide (Zepbound) is a dual agonist that activates both GLP-1 and GIP receptors. That second pathway appears to add appetite and metabolic effects, which is one explanation for the larger average weight loss seen in trials.
The side-effect profiles are similar and mostly gastrointestinal: nausea, constipation, diarrhea, reflux, and fatigue, usually strongest in the first weeks after a dose increase. Both carry a boxed warning about thyroid C-cell tumors seen in rodents and are not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN2.
Most people regain a substantial share of lost weight after stopping, because these medications treat an ongoing biological drive rather than cure it. That is why we plan for nutrition, protein intake, resistance training, and sleep from day one, and why any taper is deliberate rather than abrupt.
It depends on your medical history, insulin resistance, GI tolerance, prior medication trials, insurance coverage, and supply availability. That decision belongs in a real clinical conversation with a physician who reviews your labs and follows you through titration.
This article is general education, not medical advice, and does not create a physician-patient relationship. Prescription decisions require an individual evaluation with a licensed clinician.